rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Candel Therapeutics, Inc.

CADL · Nasdaq

Health CareBiotechnologyJust dropped out

CADL stood above a rising 150-day average in 34 of the last 52 weekly readings, and has been out of that trend for the last 1 week. It is 4.6% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Just dropped out
Weeks in an uptrend
out for 1
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$6.0M
Insider sales, 12 months
$7.1M
Officials’ trades on record
0
Institutions holding
134 (+25)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 34 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$5.8M$0$7.0MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months5
Buyers · sellers1 · 3
WhoDidSharesTraded
Paul Peter TakChief Executive Officersold59,379at $10.4611 Sep 2026filed 11 Sep 2026
Paul Peter TakChief Executive Officersold220,866at $11.5010 Sep 2026filed 11 Sep 2026
Seshu TyagarajanChief Technology Officersold7,000at $12.0017 Aug 2026filed 19 Aug 2026
Francesca BaroneChief Scientific Officersold23,447at $10.0629 Jun 2026filed 1 Jul 2026
Seshu TyagarajanChief Technology Officersold7,000at $10.0229 Jun 2026filed 1 Jul 2026
Paul B. ManningDirectorbought550,458at $5.4523 Feb 2026filed 26 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders134+25 on the quarter
New · exited41 · 15
Reported value$522.5M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
FMR LLCadded · filed 13 Aug 202610,990,535$113.2M+3,5180.0%
RTW INVESTMENTS, LPunchanged · filed 14 Aug 20266,422,018$66.1M00.0%
BlackRock, Inc.added · filed 7 Aug 20264,969,040$51.2M+1,859,998+59.8%
STATE STREET CORPadded · filed 7 Aug 20263,549,823$36.6M+2,731,265+333.7%
ACORN CAPITAL ADVISORS, LLCunchanged · filed 14 Aug 20263,497,948$36.0M00.0%
Portolan Capital Management, LLCadded · filed 14 Aug 20263,490,398$36.0M+596,073+20.6%
Saturn V Capital Management LPadded · filed 14 Aug 20263,303,686$34.0M+407,098+14.1%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,694,040$27.7M+231,283+9.4%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,571,021$16.2M+535,586+51.7%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 20261,093,905$11.3M+33,819+3.2%
31 Mar 2023 – 30 Jun 2026
2176130Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Joseph C. Papa Company insiderDirector · last 30 Sep 20262 · 0
Nicoletta Loggia Company insiderDirector · last 30 Sep 20260 · 0
Paul B. Manning Company insiderDirector · last 30 Sep 20265 · 0
Paul Peter Tak Company insiderChief Executive Officer · last 11 Sep 20263 · 9
Martine Zimmermann Company insiderDirector · last 8 Sep 20260 · 0
Seshu Tyagarajan Company insiderChief Technology Officer · last 17 Aug 20262 · 9
Mark E. Sims Company insiderChief Commercial Officer · last 6 Jul 20260 · 0
Francesca Barone Company insiderChief Scientific Officer · last 29 Jun 20261 · 7
Christopher Martell Company insiderDirector · last 23 Jun 20265 · 0
Diem Nguyen Company insiderDirector · last 23 Jun 20261 · 0
Edward J. Benz Jr. Company insiderDirector · last 23 Jun 20260 · 0
Gary J. Nabel Company insiderDirector · last 23 Jun 20260 · 0

Same industry

MRNA ModernaLeading+167%
ENTX Entera BioLeading+52%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-41.5%
Interest coverFY 2025 · to 31 Dec 2025-22.78×
Share count trendFY 2025 · to 5 Mar 202633.4%
Cash and equivalentsFY 2025 · to 31 Dec 2025$119.7M
Free cash flowFY 2025 · to 31 Dec 2025−$38.9M

Analyst forecasts

No analyst forecasts yet.